Table 2. Univariate and multivariate survival analyses for BCSS and RFS.
Variables | BCSS | RFS | |||||||
Univariate | Multivariate | Univariate | Multivariate | ||||||
P | HR | 95% CI | P | P | HR | 95% CI | P | ||
Age, year | ≤50 vs.>50 | 0.356 | 1.911 | 0.768–4.755 | 0.164 | 0.582 | 1.047 | 0.554–1.982 | 0.887 |
TNM stage | Stage I & II vs. Stage III | 0.002 | 4.217 | 1.141–15.579 | 0.031 | <0.001 | 3.554 | 1.467–8.609 | 0.005 |
Lymphovascular invasion | Negative vs. Positive | 0.060 | 1.920 | 0.397–9.277 | 0.417 | 0.039 | 1.151 | 0.398–3.331 | 0.795 |
ER status | Negative vs. Positive | 0.001 | 0.493 | 0.126–1.920 | 0.308 | 0.009 | 0.748 | 0.269–2.082 | 0.578 |
PR status | Negative vs. Positive | 0.001 | 0.560 | 0.195–1.610 | 0.282 | 0.004 | 0.644 | 0.283–1.465 | 0.294 |
HER-2 status | Negative vs. Positive | 0.045 | 1.121 | 0.350–3.595 | 0.847 | 0.061 | 1.158 | 0.513–2.613 | 0.724 |
Abbreviations: BCSS, breast cancer-specific survival; RFS, recurrence/metastasis-free survival; HR, hazard ratio; CI, confidence interval; TNM, tumor, node, metastasis; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2
Bold values denote P<0.05.